PMID- 22544725
OWN - NLM
STAT- MEDLINE
DCOM- 20130328
LR  - 20201215
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 132
IP  - 1
DP  - 2013 Jan 1
TI  - Alteration of HLA-F and HLA I antigen expression in the tumor is associated with 
      survival in patients with esophageal squamous cell carcinoma.
PG  - 82-9
LID - 10.1002/ijc.27621 [doi]
AB  - Alteration of human leukocyte antigen (HLA) expression, such as decreased HLA I 
      (HLA-A, -B and -C) antigens and elevated nonclassical HLA I antigens (HLA-E, -F 
      and -G), was reported to have an unfavorable prognosis in various cancers. In our 
      study, HLA-F expression in 105 primary esophageal squamous cell carcinoma (ESCC) 
      lesions and 62 case-matched adjacent normal tissues, and HLA I antigens among 68 
      cases were analyzed by immunohistochemistry. Data revealed that HLA-F expression 
      was observed in 58.1% (61/105) of the ESCC lesions and in 54.8% (34/62) of the 
      normal esophageal tissues. Among the 62 case-matched samples, HLA-F expression 
      (lesion vs. normal tissue) was upregulated, unchanged and downregulated in 13 
      (21.0%), 6 (9.6%) and 43 (69.4%) cases, respectively. Patients with HLA-F 
      positive had a worse survival than those with HLA-F negative (p = 0.040). 
      Patients with upregulated HLA-F expression (lesion vs. normal tissue) had 
      significantly worse survival than those with HLA-F unchanged and downregulated (p 
      = 0.010). Furthermore, decreased HLA I expression was observed in 41.2% (28/68) 
      patients and was with worse prognosis in comparison to those with preserved HLA I 
      expression (p = 0.001). Multivariate analysis using Cox's proportional hazards 
      model revealed that upregulated HLA-F expression (p = 0.026) and downregulated 
      HLA I expression (p = 0.013) could be an independent unfavorable prognostic 
      factor. In conclusion, our study provided the evidence that alteration of HLA I 
      and HLA-F antigen expression was associated with survival in patients with ESCC.
CI  - Copyright (c) 2012 UICC.
FAU - Zhang, X
AU  - Zhang X
AD  - Human Tissue Bank, Taizhou Hospital of Zhejiang Province, Wenzhou Medical 
      College, Linhai, Zhejiang, People's Republic of China.
FAU - Lin, A
AU  - Lin A
FAU - Zhang, J-G
AU  - Zhang JG
FAU - Bao, W-G
AU  - Bao WG
FAU - Xu, D-P
AU  - Xu DP
FAU - Ruan, Y-Y
AU  - Ruan YY
FAU - Yan, W-H
AU  - Yan WH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120517
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (HLA-F antigens)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Carcinoma, Squamous Cell/genetics/*immunology/pathology
MH  - Case-Control Studies
MH  - Down-Regulation
MH  - Esophageal Neoplasms/genetics/*immunology/pathology
MH  - Female
MH  - Follow-Up Studies
MH  - Gene Expression Regulation, Neoplastic/immunology
MH  - Histocompatibility Antigens Class I/*biosynthesis/genetics
MH  - Humans
MH  - Immunohistochemistry/methods
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Up-Regulation
EDAT- 2012/05/01 06:00
MHDA- 2013/03/30 06:00
CRDT- 2012/05/01 06:00
PHST- 2011/10/30 00:00 [received]
PHST- 2012/04/23 00:00 [accepted]
PHST- 2012/05/01 06:00 [entrez]
PHST- 2012/05/01 06:00 [pubmed]
PHST- 2013/03/30 06:00 [medline]
AID - 10.1002/ijc.27621 [doi]
PST - ppublish
SO  - Int J Cancer. 2013 Jan 1;132(1):82-9. doi: 10.1002/ijc.27621. Epub 2012 May 17.